Recent Investment Analysts’ Ratings Changes for Bristol Myers Squibb (BMY)

Several brokerages have updated their recommendations and price targets on shares of Bristol Myers Squibb (NYSE: BMY) in the last few weeks:

• 7/31/2026 – Bristol Myers Squibb had its “buy” rating reaffirmed by Guggenheim.
• 7/27/2026 – Bristol Myers Squibb had its “market perform” rating reaffirmed by Raymond James Financial, Inc..
• 7/27/2026 – Bristol Myers Squibb had its “market perform” rating reaffirmed by BMO Capital Markets.
• 7/16/2026 – Bristol Myers Squibb was downgraded by Weiss Ratings from “hold (c+)” to “hold (c)”.
• 7/10/2026 – Bristol Myers Squibb had its price target lowered by Bank of America Corporation from $67.00 to $66.00. They now have a “buy” rating on the stock.
• 7/6/2026 – Bristol Myers Squibb had its “neutral” rating reaffirmed by Cantor Fitzgerald. They now have a $54.00 price target on the stock.
• 7/2/2026 – Bristol Myers Squibb had its “hold (c+)” rating reaffirmed by Weiss Ratings.
• 6/27/2026 – Bristol Myers Squibb was upgraded by Wall Street Zen from “buy” to “strong-buy”.
• 6/6/2026 – Bristol Myers Squibb was downgraded by Wall Street Zen from “strong-buy” to “buy”.

Bristol Myers Squibb Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Monday, August 3rd. Stockholders of record on Thursday, July 2nd will be paid a dividend of $0.63 per share. This represents a $2.52 annualized dividend and a dividend yield of 3.9%. The ex-dividend date is Thursday, July 2nd. Bristol Myers Squibb’s dividend payout ratio is 70.79%.

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company’s core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS’s marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.